Etsy is having to spend more on marketing as the buyer churn rate goes up, the Wall Street firm said.
‘Our phones are ringing off the hook’: Amid a global downturn, the finance world is chasing Middle Eastern money
The Gulf region’s 10 largest sovereign wealth funds combined manage nearly $4 trillion, according to the Sovereign Wealth Fund Institute.
The U.S. imposed semiconductor export controls on China. Now a key EU nation is set to follow suit
The Netherlands — home to critical chip firm ASML — is embroiled in political tensions between the U.S. and China over semiconductor technology.
Ukraine war live updates: Power restored at huge nuclear plant after Russia unleashes strikes across Ukraine
Kyiv and other major cities including Lviv, Kharkiv and Odesa have been hit by a wave of Russian drone and missile strikes overnight, Ukrainian officials said.
Credit Suisse to delay its 2022 annual report after a ‘late call’ from the SEC
Credit Suisse announced that it will delay the publication of its 2022 annual report after a late call with the SEC on Wednesday night.
Meet the woman who wrote a shocking account of her life on Wall Street
Jamie Fiore Higgins, who worked at Goldman Sachs for 18 years, wants to break the “taboo” around candidly discussing workplace harassment and assault.
‘A terrible environment for equities’: Market veteran predicts when stocks will pull back — and how to trade it
Chief market strategist Chris Watling expects stocks to fall into a bear market over the next three to six months thanks to lofty valuations.
Senate Minority Leader Mitch McConnell hospitalized after falling
McConnell, R-Ky., tripped at a hotel and was taken to a hospital, a spokesperson said. Additional information about his condition was not immediately available.
Norfolk Southern CEO vows aid for ‘as long as it takes’ after toxic Ohio derailment
Norfolk Southern CEO Alan Shaw testified before a Senate panel to address the East Palestine, Ohio, train derailment.
Eli Lilly Alzheimer’s treatment solanezumab failed to slow disease progression
Solanezumab’s failure is a blow to efforts to treat Alzheimer’s in people who have not yet shown clinical symptoms.